Abstract:A robust, reproducible, and high throughput method was developed for the relative quantitative analysis of glycoprotein abundances in human serum. Instead of quantifying glycoproteins by glycopeptides in conventional quantitative glycoproteomics, glycoproteins were quantified by nonglycosylated peptides derived from the glycoprotein digest, which consists of the capture of glycoproteins in serum samples and the release of nonglycopeptides by trypsin digestion of captured glycoproteins followed by two-dimensional liquid chromatography-tandem MS analysis of released peptides. Protein quantification was achieved by comparing the spectrum counts of identified nonglycosylated peptides of glycoproteins between different samples. This method was demonstrated to have almost the same specificity and sensitivity in glycoproteins quantification as capture at glycopeptides level. The differential abundance of proteins present at as low as nanogram per milliliter levels was quantified with high confidence. The established method was applied to the analysis of human serum samples from healthy people and patients with hepatocellular carcinoma (HCC) to screen differential glycoproteins in HCC. Thirty eight glycoproteins were found with substantial concentration changes between normal and HCC serum samples, including α-fetoprotein, the only clinically used marker for HCC diagnosis. The abundance changes of three glycoproteins, i.e. galectin-3 binding protein, insulin-like growth factor binding protein 3, and thrombospondin 1, which were associated with the development of HCC, were further confirmed by enzyme-linked immunosorbent assay. In conclusion, the developed method was an effective approach to quantitatively analyze glycoproteins in human serum and could be further applied in the biomarker discovery for HCC and other cancers.

Lectin-based Glycoproteomics to Explore and Analyze Hepatocellular Carcinoma-Related Glycoprotein Markers.

Emerging Biomolecules for Practical Theranostics of Liver Hepatocellular Carcinoma.

Dysregulated Serum Metabolites in Staging of Hepatocellular Carcinoma.

Quantitative Proteomic Analysis for High-Throughput Screening of Differential Glycoproteins in Hepatocellular Carcinoma Serum

Selective Isolation and Analysis of Glycoprotein Fractions and Their Glycomes from Hepatocellular Carcinoma Sera

Identification of serum glycobiomarkers for Hepatocellular Carcinoma using lectin microarrays

Comparative serum glycoproteomics of non-metastatic and metastatic hepatocellular carcinoma by lectin affinity technology

Identification of N-glycosylation in Hepatocellular Carcinoma Patients' Serum with a Comparative Proteomic Approach.

Glypican‐3: A Promising Biomarker for Hepatocellular Carcinoma Diagnosis and Treatment

Investigation on Glycosylation Patterns of Proteins from Human Liver Cancer Cell Lines Based on the Multiplexed Proteomics Technology

Single cell glycan-linkages profiling for hepatocellular carcinoma early diagnosis using lanthanide encoded bacteriophage MS2 based ICP-MS

Glycoproteomics investigation of human hepatocellular carcinoma cell lines

Membrane Protein Glycanprofiling of Hepatocellular Carcinoma Cell with Different Metastastic Potential by Lectin Microarray*

Identification and Analysis of Altered Alpha 1,6-Fucosylated Glycoproteins Associated with Hepatocellular Carcinoma Metastasis

Proteomic Fingerprinting of N-linked Glycoproteins Involved in Hepatocellular Carcinoma

Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach

Identification of N-glycosylation sites on secreted proteins of human hepatocellular carcinoma cells with a complementary proteomics approach.

Straightforward and Highly Efficient Strategy for Hepatocellular Carcinoma Glycoprotein Biomarker Discovery Using a Nonglycopeptide-Based Mass Spectrometry Pipeline

Integrated plasma proteomics and N‐glycoproteomics reveals alterations in the N‐glycosylation in Chinese hepatocellular carcinoma patients

Proteomic Profiling of N-linked Glycoproteins Involved in Hepatocellular Carcinoma by Two-dimensional Electrophoresis and Mass Spectrometry

Development of Glycoprotein Capture-Based Label-Free Method for the High-throughput Screening of Differential Glycoproteins in Hepatocellular Carcinoma